cas 221093-39-6|| where to buy Pyridine, 2,6-dichloro-4-(methoxymethyl)-

Название продукции:Pyridine, 2,6-dichloro-4-(methoxymethyl)-

IUPAC Name:2,6-dichloro-4-(methoxymethyl)pyridine

Упаковочная единица	Доступно для заказа	Цена ($)	Количество
CM653318-1g	in stock	ƴĳƈƚ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 221093-39-6 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:221093-39-6; Молекулярная формула:C7H7Cl2NO; Точка плавления:-; Smiles-код:COCC1=CC(Cl)=NC(Cl)=C1; Плотность:

: Номер в каталоге:CM653318; Молекулярная масса:192.04; Точка кипения:; Номер Mdl:; Хранение:

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: ABBV-712; TYK2 is an attractive target for various autoimmune diseases as it regulates signal transduction downstream of IL-23 and IL-12 receptors. Selective TYK2 inhibition offers a differentiated clinical profile compared to currently approved JAK inhibitors. Scientists discovered the clinical candidate ABBV-712 in the optimization of selective TYK2 inhibitors targeting the pseudokinase domain.